YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its aggressive nature and limited therapeutic options.
• Krüpple-like factor 5 (KLF5) has been identified as a potential therapeutic target in TNBC.
• YD277, a derivative of the KLF5 inhibitor ML264, exhibits cytotoxic properties.

Purpose of the Study:

• To investigate the therapeutic potential of YD277 in triple-negative breast cancer (TNBC).
• To elucidate the mechanisms underlying YD277's anti-cancer effects in TNBC cells.
• To evaluate the in vivo efficacy of YD277 against TNBC xenografts.

Main Methods:

• Treatment of TNBC cell lines (MDA-MB-231, MDA-MB-468) with YD277.
• Cell cycle analysis and apoptosis assays.
• Western blot analysis to assess protein expression (Cyclin D1, Bcl2, Bclxl, p21, p27).
• Investigation of endoplasmic reticulum (ER) stress pathway involvement via IRE1α transcription.
• In vivo studies using MDA-MB-231 tumor xenografts in nude mice.

Main Results:

• YD277 induced significant G1 cell cycle arrest and apoptosis in TNBC cells, independent of KLF5 inhibition.
• YD277 modulated the expression of key cell cycle regulators and apoptosis-related proteins, including decreased Cyclin D1, Bcl2, Bclxl and increased p21, p27.
• The pro-apoptotic effects of YD277 were linked to the transcription of IRE1α within the ER stress pathway.
• YD277 demonstrated significant suppression of MDA-MB-231 tumor xenograft growth in vivo.

Conclusions:

• YD277 exhibits potent anti-cancer activity against triple-negative breast cancer cells through mechanisms involving cell cycle arrest and apoptosis.
• The compound's efficacy is mediated, in part, by the ER stress pathway via IRE1α.
• YD277 represents a promising chemotherapeutic candidate for the treatment of TNBC, warranting further clinical investigation.